You worked hard to lose the weight. The last thing you expected was to look in the mirror and feel like you aged ten years in six months. Here's what's actually happening — and what we can do about it.

You did everything right. The medication worked. The weight came off — sometimes faster than you expected. And then somewhere in the mirror, between the triumph of the scale and the joy of clothes that finally fit, you noticed something nobody warned you about. Your face looked different. Older, somehow. Hollower. The cheeks you had, gone. A gauntness around the temples. Under-eye shadows that makeup couldn't cover. Skin that used to be taut now sitting differently. You weren't imagining it. You weren't being vain. You were experiencing what the entire aesthetic medicine world is now calling "Ozempic face" — and you are far from alone.

At Évry Aesthetics in Elmhurst, IL, we see GLP-1 patients every week who have achieved meaningful, life-changing weight loss and are now navigating the aesthetic aftermath. We prescribe GLP-1 medications ourselves — our clinical team includes NPs with full practice authority in Illinois — and we understand both the metabolic success and the aesthetic picture that follows. The good news, delivered plainly: “Ozempic face” is real, it is well-understood, and it is highly treatable. Here is everything you need to know.

The anatomy of “Ozempic face” — and why it looks the way it does

"Ozempic face" refers to a cluster of facial changes that can occur with significant weight loss — gauntness, hollowing under the eyes, cheek volume loss, jowling, and general skin laxity. The name is imprecise — these changes can happen with weight loss from any cause — but the phenomenon is real. Evidence suggests that GLP-1 and dual GLP-1/GIP receptor agonists may contribute to rapid facial volume loss, dermal fat atrophy, and periocular hollowing. The mechanism is multifactorial, involving both weight-loss-related fat depletion and potential modulation of adipocyte differentiation.

The face is not a single fat compartment. It is a complex three-dimensional structure of layered fat pads — each sitting in a specific anatomical position, contributing to specific facial features — that deplete at different rates during weight loss. The most pronounced losses occur in the medial cheek, sub-orbicularis oculi (under-eye), and temporal fat pads. This is why Ozempic face has such a specific, recognizable appearance: it's not random deflation. It's a predictable anatomical pattern.

Temples

Temporal fat pad depletion creates visible hollowing at the sides of the forehead — a caved-in appearance that ages the face significantly and is often the first place patients notice the change

Under-Eyes

Sub-orbicularis fat loss deepens the tear trough, making the orbital rim more prominent and casting the persistent shadows that read as chronic exhaustion regardless of how well-rested the patient is

Midface & Cheeks

61% of GLP-1 patients experience midface volume loss — the deflation of the malar fat pads flattens the cheeks and causes the nasolabial folds to deepen as unsupported tissue falls forward

Jawline & Jowls

As midface volume depletes and skin loses its elastic support, the jowling effect appears — not from new tissue growth but from tissue that has lost its scaffolding and descended

How we treat “Ozempic face” — and why we do it in a specific sequence

The mistake most patients make is reaching for the first available solution — often filler — before the clinical picture is complete. The key word in 2026 is restraint. The era of overfilling has passed. For GLP-1-related facial volume loss, filler should not be used to inflate the face. It should be used strategically to restore structure, support, and light reflection. At Évry, we sequence our treatments deliberately — first ensuring weight is stable, then addressing the different dimensions of the Ozempic face picture in order of anatomical priority.

RHA® Collection Fillers

Volume restoration — temples, midface, under-eye, jawline

Step 1 — Structure

81% of healthcare providers identify hyaluronic acid fillers as the top treatment modality for GLP-1-related facial volume loss. At Évry, we use the RHA® Collection — resilient hyaluronic acid fillers engineered to move naturally with facial expressions. For Ozempic face patients, we work anatomically from the top down: temporal hollowing first, then midface volume, then the under-eye orbital rim, then jawline refinement if needed. We use the minimum effective amount to restore proportion and support — never to inflate. The goal is a face that looks like yours, not a face that looks treated.

Endoret® PRGF Plasma Gel

Under-eye restoration — autologous, no Tyndall risk

Step 2 — Under-Eye

The under-eye area is the most technically demanding zone in Ozempic face treatment — thin skin, high vascularity, and immediate visibility of any imprecision. For patients with delicate periorbital tissue or previous filler experiences that weren't ideal, we offer PRGF plasma gel — your own growth factors thermally activated into a soft gel that volumizes the tear trough while simultaneously improving tissue quality. Zero synthetic material. Zero Tyndall effect risk. The most biocompatible option available for one of the most sensitive treatment zones on the face.

Hyperdilute Radiesse®

Skin laxity — face, neck, décolleté, and body

Step 3 — Laxity

Volume loss is only half the Ozempic face picture. The other half is skin laxity — the loosening that occurs when fat pad support disappears faster than the skin can adapt. Hyperdilute Radiesse® addresses this by triggering your own collagen Types I and III and elastin production — structural tightening that develops over 3–6 months and lasts up to two years. Unlike filler, it doesn't add volume. It strengthens the tissue. For Ozempic face patients with significant laxity on the face, neck, or body, this is the most durable tissue-quality investment in our toolkit.

Rejuran® PDRN Microneedling + PRGF Skin Therapy

Skin quality — texture, luminosity, density, and barrier repair

Step 4 — Quality

Rapid weight loss affects not just volume but skin quality itself — the texture, density, and luminosity that make a face look healthy rather than depleted. PDRN microneedling paired with PRGF skin therapy addresses this dimension directly: stimulating collagen and elastin at the cellular level, reducing inflammatory burden, improving microcirculation, and restoring the dermal density that gives skin its resilience. These treatments work best after structural volume has been addressed — when the architectural foundation is back in place, the surface treatments that improve quality are able to produce their full effect.

Letybo® Neurotoxin

Expression lines and brow support — the final refinement

Step 5 — Refinement

Once volume, laxity, and skin quality have been addressed, Letybo® neurotoxin handles the final layer — softening expression lines that have deepened during the period of weight loss, supporting brow position, and addressing any platysmal banding that has become more visible as neck fat depleted. Used in this sequence — after the structural work is done — neurotoxin contributes to a comprehensive result that addresses every dimension of the Ozempic face presentation.

“Ozempic face” is not a reason to stop your medication or regret your weight loss. It's a clinical situation with clinical solutions — well-documented, well-treated, and entirely manageable with the right team. You did the hard work. The transformation you achieved is real, meaningful, and worth protecting. Let us help you make sure the face in the mirror reflects the version of yourself that you've worked so hard to become.

If you're in Elmhurst, Oak Brook, Wheaton, Lombard, or the greater Chicago area — complimentary consultations are available. Come in and let's talk about the full picture.

Book your complimentary consultation

Évry Aesthetics · 597 N York St, Elmhurst, IL · (630) 333-4285